de Ameriprise Vertex Pharmaceuticals VRTX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 1294 M | Vender |
2,604,822
-28,659
| -1% | -USD 12.7 M | 0.26% | 75 |
|
|
2026
Q1 | USD 1176 M | Comprar |
2,633,481
+369,749
| +16% | +USD 172 M | 0.27% | 81 |
|
|
2025
Q4 | USD 1026 M | Vender |
2,263,732
-13,195
| -0.6% | -USD 5.69 M | 0.23% | 85 |
|
|
2025
Q3 | USD 892 M | Comprar |
2,276,927
+95,565
| +4% | +USD 39.9 M | 0.2% | 100 |
|
|
2025
Q2 | USD 971 M | Vender |
2,181,362
-54,107
| -2% | -USD 24.9 M | 0.24% | 87 |
|
|
2025
Q1 | USD 1084 M | Comprar |
2,235,469
+219,946
| +11% | +USD 102 M | 0.29% | 67 |
|
|
2024
Q4 | USD 812 M | Comprar |
2,015,523
+143,713
| +8% | +USD 66.6 M | 0.21% | 99 |
|
|
2024
Q3 | USD 871 M | Vender |
1,871,810
-182,971
| -9% | -USD 87.9 M | 0.22% | 93 |
|
|
2024
Q2 | USD 963 M | Vender |
2,054,781
-170,526
| -8% | -USD 74 M | 0.26% | 78 |
|
|
2024
Q1 | USD 930 M | Vender |
2,225,307
-284,722
| -11% | -USD 120 M | 0.26% | 82 |
|
|
2023
Q4 | USD 1021 M | Vender |
2,510,029
-427,783
| -15% | -USD 158 M | 0.31% | 65 |
|
|
2023
Q3 | USD 1022 M | Vender |
2,937,812
-86,031
| -3% | -USD 30.1 M | 0.34% | 59 |
|
|
2023
Q2 | USD 1064 M | Vender |
3,023,843
-366,017
| -11% | -USD 123 M | 0.33% | 62 |
|
|
2023
Q1 | USD 1068 M | Vender |
3,389,860
-188,787
| -5% | -USD 56.6 M | 0.35% | 57 |
|
|
2022
Q4 | USD 1033 M | Vender |
3,578,647
-463,346
| -11% | -USD 141 M | 0.35% | 60 |
|
|
2022
Q3 | USD 1171 M | Vender |
4,041,993
-520,956
| -11% | -USD 150 M | 0.43% | 41 |
|
|
2022
Q2 | USD 1285 M | Vender |
4,562,949
-384,414
| -8% | -USD 103 M | 0.45% | 40 |
|
|
2022
Q1 | USD 1290 M | Comprar |
4,947,363
+524,167
| +12% | +USD 124 M | 0.38% | 50 |
|
|
2021
Q4 | USD 969 M | Comprar |
4,423,196
+1,034,106
| +31% | +USD 201 M | 0.27% | 74 |
|
|
2021
Q3 | USD 615 M | Comprar |
3,389,090
+650,315
| +24% | +USD 127 M | 0.2% | 111 |
|
|
2021
Q2 | USD 552 M | Comprar |
2,738,775
+820,708
| +43% | +USD 172 M | 0.17% | 129 |
|
|
2021
Q1 | USD 412 M | Comprar |
1,918,067
+1,100,467
| +135% | +USD 242 M | 0.14% | 161 |
|
|
2020
Q4 | USD 193 M | Vender |
817,600
-22,268
| -3% | -USD 5.11 M | 0.07% | 296 |
|
|
2020
Q3 | USD 228 M | Vender |
839,868
-444,227
| -35% | -USD 123 M | 0.09% | 231 |
|
|
2020
Q2 | USD 373 M | Vender |
1,284,095
-888,799
| -41% | -USD 241 M | 0.16% | 136 |
|
|
2020
Q1 | USD 517 M | Vender |
2,172,894
-236,171
| -10% | -USD 54.2 M | 0.27% | 73 |
|
|
2019
Q4 | USD 527 M | Comprar |
2,409,065
+30,299
| +1% | +USD 6.13 M | 0.22% | 91 |
|
|
2019
Q3 | USD 403 M | Vender |
2,378,766
-62,955
| -3% | -USD 11.1 M | 0.18% | 114 |
|
|
2019
Q2 | USD 448 M | Comprar |
2,441,721
+78,258
| +3% | +USD 13.7 M | 0.2% | 103 |
|
|
2019
Q1 | USD 435 M | Vender |
2,363,463
-1,986,539
| -46% | -USD 367 M | 0.2% | 100 |
|
|
2018
Q4 | USD 721 M | Vender |
4,350,002
-1,393,382
| -24% | -USD 241 M | 0.36% | 51 |
|
|
2018
Q3 | USD 1105 M | Vender |
5,743,384
-82,081
| -1% | -USD 14.6 M | 0.39% | 49 |
|
|
2018
Q2 | USD 988 M | Comprar |
5,825,465
+220,446
| +4% | +USD 34.2 M | 0.44% | 39 |
|
|
2018
Q1 | USD 914 M | Comprar |
5,605,019
+349,639
| +7% | +USD 57.1 M | 0.41% | 42 |
|
|
2017
Q4 | USD 787 M | Vender |
5,255,380
-176,700
| -3% | -USD 26.2 M | 0.36% | 56 |
|
|
2017
Q3 | USD 826 M | Vender |
5,432,080
-973,672
| -15% | -USD 147 M | 0.39% | 49 |
|
|
2017
Q2 | USD 826 M | Vender |
6,405,752
-1,832,449
| -22% | -USD 221 M | 0.41% | 42 |
|
|
2017
Q1 | USD 901 M | Vender |
8,238,201
-468,434
| -5% | -USD 41.2 M | 0.47% | 35 |
|
|
2016
Q4 | USD 641 M | Comprar |
8,706,635
+11,204
| +0.1% | +USD 912 k | 0.35% | 53 |
|
|
2016
Q3 | USD 758 M | Vender |
8,695,431
-328,644
| -4% | -USD 31.1 M | 0.42% | 43 |
|
|
2016
Q2 | USD 776 M | Vender |
9,024,075
-379,072
| -4% | -USD 32.8 M | 0.45% | 43 |
|
|
2016
Q1 | USD 747 M | Vender |
9,403,147
-187,047
| -2% | -USD 16.9 M | 0.45% | 44 |
|
|
2015
Q4 | USD 1207 M | Vender |
9,590,194
-571,203
| -6% | -USD 69 M | 0.71% | 26 |
|
|
2015
Q3 | USD 1058 M | Comprar |
10,161,397
+286,836
| +3% | +USD 36.9 M | 0.66% | 26 |
|
|
2015
Q2 | USD 1219 M | Vender |
9,874,561
-81,333
| -0.8% | -USD 10.2 M | 0.69% | 19 |
|
|
2015
Q1 | USD 1175 M | Comprar |
9,955,894
+642,075
| +7% | +USD 76.9 M | 0.67% | 23 |
|
|
2014
Q4 | USD 1106 M | Vender |
9,313,819
-184,044
| -2% | -USD 20.7 M | 0.64% | 22 |
|
|
2014
Q3 | USD 1067 M | Comprar |
9,497,863
+2,419,288
| +34% | +USD 230 M | 0.64% | 21 |
|
|
2014
Q2 | USD 670 M | Vender |
7,078,575
-1,047,185
| -13% | -USD 73.4 M | 0.4% | 46 |
|
|
2014
Q1 | USD 575 M | Comprar |
8,125,760
+334,295
| +4% | +USD 26.5 M | 0.35% | 63 |
|
|
2013
Q4 | USD 579 M | Comprar |
7,791,465
+1,833,313
| +31% | +USD 128 M | 0.35% | 59 |
|
|
2013
Q3 | USD 452 M | Comprar |
5,958,152
+1,375,662
| +30% | +USD 109 M | 0.3% | 65 |
|
|
2013
Q2 | USD 366 M | Comprar |
+4,582,490
| Nuevas | +USD 337 M | 0.25% | 81 |
|
Otros fondos que tienen VRTX en su cartera
Posición de Ameriprise en VRTX: resumen de T2 2026
Ameriprise redujo su participación en Vertex Pharmaceuticals (VRTX) en 1.1% durante T2 2026, al vender acciones por un valor estimado de USD 12.7 M, y conservó 2,604,822 acciones valuadas en USD 1294 M. La posición representa 0.26% de la cartera y ocupa el puesto #75.
Ameriprise reportó por primera vez una posición en VRTX en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 1,767 fondos que sigue Wall St. Rank mantienen una posición en VRTX.
- Al cierre de T2 2026, Ameriprise tenía 2,604,822 acciones de Vertex Pharmaceuticals con un valor de USD 1294 M.
- Ameriprise vendió 28,659 acciones de Vertex Pharmaceuticals en T2 2026, por un valor estimado de USD 12.7 M.
- Vertex Pharmaceuticals representó 0.26% de la cartera de Ameriprise en T2 2026 y fue su posición número 75.
- Ameriprise reportó por primera vez una posición en Vertex Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 1,767 fondos que sigue Wall St. Rank tenían Vertex Pharmaceuticals en cartera.
Según el Informe 13F de Ameriprise correspondiente a T2 2026, presentado el 14 ago 2026.